

Caroline Victorri-Vigneau

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4188948/publications.pdf>

Version: 2024-02-01

62
papers

974
citations

471061

17
h-index

500791

28
g-index

79
all docs

79
docs citations

79
times ranked

974
citing authors

#	ARTICLE	IF	CITATIONS
1	ZORRO: When the mask falls offâ€”Comment. British Journal of Clinical Pharmacology, 2022, 88, 2450-2451.	1.1	0
2	Did the pattern of use of zolpidem change since the enforcement of a new prescription rule? A latent class analysis using the French health insurance database. Expert Opinion on Drug Safety, 2022, , 1-10.	1.0	2
3	Perception of the Regulatory Change for Zolpidem Prescription by French General Practitioners and Its Relation to Prescription Behavior. Journal of Clinical Medicine, 2022, 11, 2176.	1.0	3
4	Tenâ€”year trend of opioid and nonopioid analgesic use in the French adult population. British Journal of Clinical Pharmacology, 2021, 87, 555-564.	1.1	19
5	Benzodiazepine withdrawal in older people: what is the prevalence, what are the signs, and which patients?. European Journal of Clinical Pharmacology, 2021, 77, 171-177.	0.8	11
6	CYP1A2 and tobacco interaction: a major pharmacokinetic challenge during smoking cessation. Drug Metabolism Reviews, 2021, 53, 30-44.	1.5	7
7	Are Seniors Dependent on Benzodiazepines? A National Clinical Survey of Substance Use Disorder. Clinical Pharmacology and Therapeutics, 2021, 109, 528-535.	2.3	6
8	Change in the regulatory framework for zolpidem: What is the impact on the landscape of the prescription of sedative medications? The French national ZORRO study. British Journal of Clinical Pharmacology, 2021, 87, 3310-3319.	1.1	14
9	What Differs between Patients under Methadone and under Buprenorphine for Opioid Use Disorder (OUD) in Daily Clinical Practice in France? A Short Report. International Journal of Environmental Research and Public Health, 2021, 18, 1425.	1.2	1
10	Descriptive analysis of sickle cell patients living in France: The PHEDRE cross-sectional study. PLoS ONE, 2021, 16, e0248649.	1.1	1
11	What about regular hematological monitoring during clozapine treatment? A compliance analysis using the French health insurance database. Expert Opinion on Drug Safety, 2021, 20, 1247-1256.	1.0	1
12	Usage rÃ©crÃ©atif du protoxyde dâ€™azote: mÃ©faits et mise en garde. La Presse MÃ©dicale Formation, 2021, 2, 567-567.	0.1	0
13	Poppers Use and High Methaemoglobinaemia: â€”Dangerous Liaisonsâ€™. Pharmaceuticals, 2021, 14, 1061.	1.7	7
14	Regulatory Framework Implementation for the Prescription of Zolpidem in France, What Impact in the Older People?. International Journal of Environmental Research and Public Health, 2021, 18, 12099.	1.2	2
15	Impact of Secured Prescription Implementation for Zolpidem on Hypnotics Use in France: A Time-Series Analysis on National Data. Annals of Family Medicine, 2020, 18, 345-348.	0.9	9
16	Prevalence of zolpidem use in France halved after secure prescription pads implementation in 2017: A SNDS database nested cohort study. PLoS ONE, 2020, 15, e0228495.	1.1	9
17	Do older people know why they take benzodiazepines? A national French crossâ€”sectional survey of longâ€”term consumers. International Journal of Geriatric Psychiatry, 2020, 35, 870-876.	1.3	6
18	Le syndrome dâ€™hyperÃ©mÃ©se cannabinoïde. La Presse MÃ©dicale Formation, 2020, 1, 378-383.	0.1	1

#	ARTICLE	IF	CITATIONS
19	Cannabinoid Hyperemesis Syndrome Among Pregnant Women: Beyond Diagnosis—Potentially Harmful Consequences. <i>Journal of Studies on Alcohol and Drugs</i> , 2020, 81, 824-825.	0.6	2
20	Cannabinoid Hyperemesis Syndrome Among Pregnant Women: Beyond Diagnosis—Potentially Harmful Consequences. <i>Journal of Studies on Alcohol and Drugs</i> , 2020, 81, 824-825.	0.6	0
21	Title is missing!. , 2020, 15, e0228495.		0
22	Title is missing!. , 2020, 15, e0228495.		0
23	Title is missing!. , 2020, 15, e0228495.		0
24	Title is missing!. , 2020, 15, e0228495.		0
25	High prevalence of kaolin consumption in migrant women living in a major urban area of France: A cross-sectional investigation. <i>PLoS ONE</i> , 2019, 14, e0220557.	1.1	5
26	Nitrous Oxide: What do we Know about its use Disorder Potential? Results of the French Monitoring Centre for Addiction Network Survey and Literature Review. <i>Substance Abuse</i> , 2019, 40, 33-42.	1.1	27
27	Relevance of CYP2B6 and CYP2D6 genotypes to methadone pharmacokinetics and response in the OPAL study. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1538-1543.	1.1	16
28	Prevalence of Coaddictions and Rate of Successful Treatment Among a French Sample of Opioid-Dependent Patients With Long-Term Opioid Substitution Therapy: The OPAL Study. <i>Frontiers in Psychiatry</i> , 2019, 10, 726.	1.3	5
29	Consumption of psychoactive substances in prison: Between initiation and improvement, what trajectories occur after incarceration? COSMOS study data. <i>PLoS ONE</i> , 2019, 14, e0225189.	1.1	12
30	Medicated or not medicated hypnotic substance use: strategies in sleep disorders among patients of community pharmacy. <i>Fundamental and Clinical Pharmacology</i> , 2019, 33, 216-222.	1.0	0
31	Assessment of an Equimolar Mixture of Oxygen and Nitrous Oxide: Effects in Pediatric Dentistry. <i>International Journal of Clinical Pediatric Dentistry</i> , 2019, 12, 429-436.	0.3	8
32	Poppers regulation for public sale: No measure in France yet. <i>Therapie</i> , 2018, 73, 217-221.	0.6	6
33	Dopamine Agonists and Impulse Control Disorders: A Complex Association. <i>Drug Safety</i> , 2018, 41, 19-75.	1.4	101
34	Response to the Letter to the Editor Regarding “Baclofen and Alcohol-Dependent Patients: A Real Risk of Severe Self-Poisoning.” <i>Basic and Clinical Pharmacology and Toxicology</i> , 2018, 122, 7-8.	1.2	0
35	Cannabinoid hyperemesis syndrome: Review of the literature and of cases reported to the French addictovigilance network. <i>Drug and Alcohol Dependence</i> , 2018, 182, 27-32.	1.6	23
36	Interaction between CYP2D6 inhibitor antidepressants and codeine: is this relevant?. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 879-886.	1.5	12

#	ARTICLE	IF	CITATIONS
37	Opioid Antagonists for Pharmacological Treatment of Gambling Disorder: Are they Relevant?. <i>Current Neuropharmacology</i> , 2018, 16, 1418-1432.	1.4	24
38	Evaluation of problematic psychoactive substances use in people placed in police custody. <i>Journal of Clinical Forensic and Legal Medicine</i> , 2017, 49, 24-32.	0.5	8
39	Baclofen and Alcohol-Dependent Patients: A Real Risk of Severe Self-Poisoning. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2017, 121, 353-359.	1.2	23
40	The French addictovigilance network clinical assessment: Z-drugs, true false twins. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 1063-1069.	1.0	18
41	Parachuting: a dangerous trend in recreational psychoactive substance delivery. <i>Expert Opinion on Drug Delivery</i> , 2017, 14, 491-498.	2.4	3
42	Multicentre study for validation of the French addictovigilance network reports assessment tool. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 1030-1039.	1.1	4
43	Pharmacists' different profiles characterization about opioid substitution treatments. <i>Therapie</i> , 2016, 71, 379-387.	0.6	2
44	Use of psychotropic drug urine test strips in opiate maintenance therapy: A clinical assessment of its advantages. <i>Substance Abuse</i> , 2016, 37, 584-590.	1.1	2
45	Medical complications of psychoactive substances with abuse risks: Detection and assessment by the network of French addictovigilance centres. <i>Therapie</i> , 2016, 71, 563-573.	0.6	9
46	Pathological Gambling Associated With Aripiprazole or Dopamine Replacement Therapy. <i>Journal of Clinical Psychopharmacology</i> , 2016, 36, 63-70.	0.7	38
47	PHEDRE trial protocol – observational study of the prevalence of problematic use of Equimolar Mixture of Oxygen and Nitrous Oxide (EMONO) and analgesics in the French sickle-cell disease population. <i>BMC Psychiatry</i> , 2015, 15, 281.	1.1	4
48	On Comparison of Clustering Methods for Pharmacoepidemiological Data. <i>Journal of Biopharmaceutical Statistics</i> , 2015, 25, 843-856.	0.4	7
49	Fortune telling addiction: Unfortunately a serious topic about a case report. <i>Journal of Behavioral Addictions</i> , 2015, 4, 27-31.	1.9	17
50	Dependence on Prescription Benzodiazepines and Z-drugs Among Young to Middle-aged Patients in France. <i>Substance Use and Misuse</i> , 2015, 50, 320-327.	0.7	22
51	Benzodiazepines Consumption: Does Dependence Vary with Age?. <i>Substance Use and Misuse</i> , 2014, 49, 1417-1425.	0.7	15
52	Designing a tool allowing for a standardized assessment of resistance to drug diversion. <i>Expert Opinion on Drug Delivery</i> , 2014, 11, 995-1004.	2.4	3
53	Did the new French pay-for-performance system modify benzodiazepine prescribing practices?. <i>BMC Health Services Research</i> , 2014, 14, 301.	0.9	25
54	An Update on Zolpidem Abuse and Dependence. <i>Journal of Addictive Diseases</i> , 2014, 33, 15-23.	0.8	55

#	ARTICLE	IF	CITATIONS
55	Crushed and Injected Buprenorphine Tablets: Characteristics of Princeps and Generic Solutions. PLoS ONE, 2014, 9, e113991.	1.1	13
56	Pharmacoepidemiological characterisation of zolpidem and zopiclone usage. European Journal of Clinical Pharmacology, 2013, 69, 1965-1972.	0.8	41
57	Pharmacoepidemiological characterization of psychotropic drugs consumption using a latent class analysis. International Clinical Psychopharmacology, 2011, 26, 54-62.	0.9	17
58	Management of cannabis use during pregnancy: an assessment of healthcare professionals' practices. Pharmacoepidemiology and Drug Safety, 2011, 20, 464-473.	0.9	9
59	Epidemiological Characterization of Drug Overconsumption: The Example of Antidepressants. Journal of Addictive Diseases, 2011, 30, 342-350.	0.8	6
60	Diuretic drug therapy monitoring in the elderly: a cohort study. European Journal of Clinical Pharmacology, 2008, 64, 433-437.	0.8	9
61	Evidence of zolpidem abuse and dependence: results of the French Centre for Evaluation and Information on Pharmacodependence (CEIP) network survey. British Journal of Clinical Pharmacology, 2007, 64, 198-209.	1.1	171
62	How a novel programme for increasing awareness of health professionals resulted in a 14% decrease in patients using excessive doses of psychotropic drugs in western France. European Journal of Clinical Pharmacology, 2006, 62, 311-316.	0.8	18